TITLE

Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival

AUTHOR(S)
Walensky, Rochelle P.; Wood, Robin; Weinstein, Milton C.; Martinson, Neil A.; Losina, Elena; Fofana, Mariam O.; Goldie, Sue J.; Divi, Nomita; Yazdanpanah, Yazdan; Bingxia Wang; Paltiel, A. David; Freedberg, Kenneth A.
PUB. DATE
May 2008
SOURCE
Journal of Infectious Diseases;5/1/2008, Vol. 197 Issue 9, p1324
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012. Methods. Using a simulation model of HIV infection with South African data, we projected HIV-associated mortality with and without effective ART for an adult cohort in need of therapy (2007) and for adults who became eligible for treatment (2008 -2012). We compared 5 scale-up scenarios: (1) zero growth, with a total of 100,000 new treatment slots; (2) constant growth, with 600,000; (3) moderate growth, with 2.1 million; (4) rapid growth, with 2.4 million); and (5) full capacity, with 3.2 million. Results. Our projections showed that by 2011, the rapid growth scenario fully met the South African need for ART; by 2012, the moderate scenario met 97% of the need, but the zero and constant growth scenarios met only 28% and 52% of the need, respectively. The latter scenarios resulted in 364,000 and 831,000 people alive and on ART in 2012. From 2007 to 2012, cumulative deaths in South Africa ranged from 2.5 million under the zero growth scenario to 1.2 million under the rapid growth scenario. Conclusions. Alternative ART scale-up scenarios in South Africa will lead to differences in the death rate that amount to more than 1.2 million deaths by 2012. More rapid scale-up remains critically important.
ACCESSION #
32039549

 

Related Articles

  • The ART of HIV services scale-up.  // PharmacoEconomics & Outcomes News;8/26/2006, Issue 510, p8 

    The article presents the results of a open cohort study which determined the feasibility and early outcomes of the provision of HIV and AIDS services to 21,755 antiretroviral-naive patients at 18 primary care facilities in Lusaka, Zambia. The study found that a rapid increase in HIV and AIDS...

  • Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation Cohort. Taisheng Li; Yi Dai; Jiqiu Kuang; Jingmei Jiang; Yang Han; Zhifeng Qiu; Jing Xie; Lingyan Zuo; Yanling Li // PLoS Clinical Trials;Dec2008, Vol. 5 Issue 12, Special section p1 

    Background: The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection. Methodology: This was a prospective, multicenter study. 198 antiretroviral-naiuml;ve HIV-1...

  • Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Franceschi, S.; Dal Maso, L.; Rickenbach, M.; Polesel, J.; Hirschel, B.; Cavassini, M.; Bordoni, A.; Elzi, L.; Ess, S.; Jundt, G.; Mueller, N.; Clifford, G. M. // British Journal of Cancer;9/2/2008, Vol. 99 Issue 5, p800 

    Between 1984 and 2006, 12 959 people with HIV/AIDS (PWHA) in the Swiss HIV Cohort Study contributed a total of 73 412 person-years (py) of follow-up, 35 551 of which derived from PWHA treated with highly active antiretroviral therapy (HAART). Five hundred and ninety-seven incident Kaposi sarcoma...

  • Comparison of Methods to Correct Survival Estimates and Survival Regression Analysis on a Large HIV African Cohort. Henriques, Julie; Pujades-Rodriguez, Mar; McGuire, Megan; Szumilin, Elisabeth; Iwaz, Jean; Etard, Jean-François; Ecochard, René // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Objective: The evaluation of HIV treatment programs is generally based on an estimation of survival among patients receiving antiretroviral treatment (ART). In large HIV programs, loss to follow-up (LFU) rates remain high despite active patient tracing, which is likely to bias survival estimates...

  • Cohort profile: the TREAT Asia pediatric HIV observational database. Kariminia, Azar; Chokephaibulkit, Kulkanya; Pang, Joselyn; Lumbiganon, Pagakrong; Hansudewechakul, Rawiwan; Amin, Janaki; Kumarasamy, Nagalingeswaran; Puthanakit, Thanyawee; Kurniati, Nia; Nik Yusoff, Nik Khairulddin; Saphonn, Vonthanak; Fong, Siew Moy; Razali, Kamarul; Nallusamy, Revathy; Sohn, Annette H; Sirisanthana, Virat // International Journal of Epidemiology;Feb2011, Vol. 40 Issue 1, p15 

    No abstract available.

  • How many will live with HIV?  // Family Planning Perspectives;Sep/Oct94, Vol. 26 Issue 5, p196 

    The article reports that British researchers have projected that as many as one in four individuals infected with the human immunodeficiency virus (HIV) may live free of acquired immunodeficiency syndrome (AIDS) for up to 20 years. They based their estimates on data from 111 hemophiliacs...

  • AIDS.  // Africa Health;Jan2012, Vol. 34 Issue 2, p51 

    The article highlights medical studies related to AIDS. A trial Mozambique shows that point-of-care CD4 cell testing significantly led to increased use of antiretroviral therapy (ART) of HIV-infected patients. A randomised trial in South Africa reveals that the incidence of death or AIDS to...

  • International Research & Opinion.  // PharmacoEconomics & Outcomes News;1/27/2007, Issue 520, p6 

    The article offers results of medical studies. According to the findings of a multicenter study, consumption of antibacterial agents to treat bloodstream infections affects the development antimicrobial resistance. A study in Malawi reveals that AIDS patients taking antiretrovirals and given...

  • There's hope -- early observations of ARV treatment roll out in South Africa. Abah, S. J.; Addo, E.; Adjei, P. C.; Arhin, P.; Barami, A. A. S.; Byarugaba, M. A.; Chibuta, C. S.; Chowdhury, A. K.; Dlamini, L.; Ekezie, C. C.; Essobe, J.; Gerrits, T.; Gitau, L. N.; Hadiyono, J. E. P.; Irunde, H.; Kafoa, B.; Kekana, L.; Kgatlwane, J.; Kibria, G.; Kwasa, R. // Essential Drugs Monitor;2005, Issue 34, p16 

    The article discusses a study which examined the adherence to antiretroviral (ARV) drugs among people living with HIV/AIDS (PLWHA) in South Africa. Some of the factors affecting adherence to ARV treatment include perceived quality of care, privacy, respectful treatment, waiting time and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics